Jasper Therapeutics Inc
Change company Symbol lookup
Select an option...
JSPR Jasper Therapeutics Inc
UVV Universal Corp
LNC Lincoln National Corp
FMCCG Federal Home Loan Mortgage Corp
CSAN Cosan SA
SAIC Science Applications International Corp
MUR Murphy Oil Corp
SPHD Invesco S&P 500® High Dividend Low Volatility ETF
CODI Compass Diversified Holdings
MDRRP Medalist Diversified Reit Inc
Go

Company profile

Jasper Therapeutics, Inc., formerly Amplitude Healthcare Acquisition Corporation, is a biotechnology company focused on hematopoietic cell transplant therapies. The Company has developed programs, such as JSP191, an anti-CD117 monoclonal antibody, which is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It is designed to enable curative allogeneic and autologous hematopoietic cell transplants and gene therapies. The Company also provides a preclinical engineered hematopoietic stem cell (eHSC) platform, which is designed to overcome limitations of allogeneic and autologous gene-edited stem cell grafts. Its programs are used to cure and expand hematopoietic stem cell therapy to cure patients with life-threatening cancers, thalassemia, sickle cell diseases, genetic diseases and autoimmune diseases.

Closing Price
$4.36
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
4.66
Day's Low
4.25
Volume
(Light)
Volume:
51,421

10-day average volume:
92,762
51,421

Upcoming Events

JSPR's fiscal year ends in December
There are no upcoming events for JSPR

Past Earnings

This page reports .
DateEvent descriptionEarnings per
share actual
Earnings
estimate range
Previous year's
actual
November 12, 2021Q3 2021 Earnings Release-$0.69-$0.39 to -$0.17--

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

, , , Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.